A randomized controlled trial to test efficacy and safety of thrombectomy in stroke with extended lesion and extended time window. Issue 1 (January 2019)

• Record Type: Journal Article
• Authors: Bendszus, Martin; Bonekamp, Susanne; Berge, Eivind; Boutitie, Florent; Brouwer, Patrick; Gizewski, Elke; Krajina, Antonin; Pierot, Laurent; Randall, Gary; Simonsen, Claus Z.; Zeleňák, Kamil; Fiehler, Jens; Thomalla, Götz
• Is Part Of: International journal of stroke. Volume 14:Issue 1(2019)
• Page Start: 87
• Page End: 93
• Publication Date: 2019-01
• Subjects: Acute stroke therapy -- intervention -- ischemic stroke -- protocols -- radiology -- stroke -- therapy -- treatment; 616.8005
• DOI: 10.1177/1747493018798558
• Languages: English
• ISSNs: 1747-4930

Abstract

Rationale: The benefit of thrombectomy in patients with intracranial large vessel occlusion of the anterior circulation has been shown in selected patients in previous randomized controlled trials, but patients with extended ischemic lesions were excluded in the majority of these trials. TENSION aims to demonstrate efficacy and safety of thrombectomy in patients with extended lesions in an extended time window (up to 12 h from onset or from last seen well). Design: TENSION is an investigator-initiated, randomized controlled, open label, blinded endpoint, European, two-arm, postmarket study to compare the safety and effectiveness of thrombectomy as compared to best medical care alone in stroke patients with extended stroke lesions defined by an Alberta Stroke Program Early Computed Tomography Scan score of 3–5 and in an extended time window. In an adaptive design study, up to 665 patients will be randomized. Outcomes: Primary efficacy endpoint will be clinical outcome defined by the modified Rankin Scale at 90-day poststroke. The main safety endpoint will be death and dependency (modified Rankin Scale 4–6) at 90 days. Additional effect measures include adverse events, health-related quality of life, poststroke depression, and costs utility assessment. Discussion: TENSION may make effective treatment available for patients with severe stroke in an extended time window, thereby improving functional outcome and quality of life of thousands of stroke patients and reducing the individual, societal, and economic burden of death and disability resulting from severe stroke. TENSION is registered at ClinicalTrials.gov (ClinicalTrials.gov Identifier NCT03094715).